Ic-MPGN
Clinical trials for Ic-MPGN explained in plain language.
Never miss a new study
Get alerted when new Ic-MPGN trials appear
Sign up with your email to follow new studies for Ic-MPGN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to stop kidney disease from coming back after transplant
Disease control CompletedThis phase 2 study tested a drug called pegcetacoplan in 13 kidney transplant patients whose original kidney disease (C3G or IC-MPGN) had come back. The goal was to see if the drug could reduce signs of disease activity in the kidney. The study was small and early-stage, so resul…
Matched conditions: IC-MPGN
Phase 2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo twice a week for 2…
Matched conditions: IC-MPGN
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC